Skip to main content
. 2023 Mar 24;29:e938427-1–e938427-8. doi: 10.12659/MSM.938427

Table 3.

Comparison of clinical symptoms and signs between the survivor and non-survivor groups.

N Survivors (n=59) Non-survivors (n=10) χ2 P
Headache 26 22 (37.3) 4 (40.0) 0.027 0.870
Chills 47 41 (69.5) 6 (60.0) 0.355 0.551
Muscle soreness 41 36 (61.0) 5 (50.0) 0.430 0.512
Joint pain 30 28 (47.5) 2 (20.0) 2.623 0.105
Nausea and vomiting 51 43 (72.9) 8 (80.0) 0.225 0.635
Lack of appetite 68 59 (100.0) 9 (90.0) # 0.145
Abdominal pain 15 13 (22.0) 2 (20.0) 0.021 0.885
Diarrhea 29 24 (40.7) 5 (50.0) 0.305 0.581
Cough 34 31 (52.5) 3 (30.0) 1.738 0.187
Hemoptysis 29 26 (44.1) 3 (30.0) 0.695 0.405
Melena 3 3 (5.1) 0 (0.0) # 1.000
Subcutaneous hemorrhagic spot 41 33 (55.9) 8 (80.0) 2.054 0.152
Lymphadenectasis 58 49 (83.1) 9 (90.0) 0.308 0.579
Pulmonary rales 40 33 (55.9) 7 (70.0) 0.695 0.405
Gastrointestinal bleeding 5 4 (6.8) 1 (10.0) # 0.555
Sinus tachycardia 6 5 (8.5) 1 (10.0) # 1.000
Sinus bradycardia 13 10 (16.9) 3 (30.0) 0.952 0.329
Premature beat 11 8 (13.6) 3 (30.0) 1.725 0.189
Conduction block 3 3 (5.1) 0 (0.0) # 1.000
Atrial fibrillation 10 8 (13.6) 2 (20.0) 0.286 0.593
Abnormal t wave 17 16 (27.1) 1 (10.0) 1.350 0.245
#

indicates that Fisher’s exact test was used.